Knight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Purchases 6,200 Shares

Knight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan bought 6,200 shares of the business's stock in a transaction that occurred on Monday, April 1st. The shares were bought at an average price of C$5.25 per share, with a total value of C$32,550.00.

Sime Armoyan also recently made the following trade(s):

• On Monday, March 25th, Sime Armoyan purchased 351,000 shares of Knight Therapeutics stock. The stock was acquired at an average cost of C$5.25 per share, for a total transaction of C$1,842,750.00.
• On Monday, January 22nd, Sime Armoyan sold 28,200 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.75, for a total transaction of C$162,150.00.
• On Friday, January 19th, Sime Armoyan sold 91,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.75, for a total transaction of C$523,250.00.

Knight Therapeutics Stock Up 2.2 %

GUD stock traded up C$0.12 during mid-day trading on Monday, hitting C$5.54. 61,751 shares of the company were exchanged, compared to its average volume of 75,726. The company has a debt-to-equity ratio of 9.25, a quick ratio of 1.79 and a current ratio of 3.20. The firm has a market cap of C$560.48 million, a P/E ratio of -34.06, a P/E/G ratio of -1,013.50 and a beta of 0.49. The firm's 50 day simple moving average is C$5.43 and its 200 day simple moving average is C$5.17. Knight Therapeutics Inc. has a 1-year low of C$4.35 and a 1-year high of C$5.75.

Wall Street Analysts Forecast Growth

GUD has been the topic of a number of research reports. Raymond James upped their target price on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the company an "outperform" rating in a research report on Wednesday, March 6th. Royal Bank of Canada upped their target price on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the company an "outperform" rating in a research report on Friday, March 22nd.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.